COMP <GO>
CME vs MS // FORWARD P/E MULTIPLE
CME Group Inc. (NASDAQ) VS. Morgan Stanley (NYSE) • 15-METRIC TALLY: CME 10
— MS 4
▲ FORWARD P/E MULTIPLE LEADER: MS
LAST: $303.14 (+2.27%) • MKT CAP: $106.10B
forward-pe
24.3x
LAST: $184.30 (-3.00%) • MKT CAP: $298.41B
forward-pe
16.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CME VS. MS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CME | MS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 41.00% | 0.00 | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 3.50% | 3.00% | +0.50 | CME | /roic <GO> |
| EV/EBITDA & P/E Valuation | 40.2x | 31.0x | +9.20 | MS | /valuation <GO> |
| Free Cash Flow Yield | 3.95% | -7.25% | +11.20 | CME | /fcf-yield <GO> |
| Operating Margin | 64.90% | 24.60% | +40.30 | CME | /operating-margins <GO> |
| Net Profit Margin | 62.50% | 20.20% | +42.30 | CME | /net-margins <GO> |
| Revenue Growth (YoY) | 6.40% | 5.50% | +0.90 | CME | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 3.71% | 2.21% | +1.50 | CME | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.55 | 0.46 | +0.09 | CME | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 5/9 | +3.00 | CME | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 7.00% | -0.10 | CME | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 65.4 | 43.3 | +22.11 | CME | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.01 | 1.04 | -0.03 | MS | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 24.3x | 16.5x | +7.80 | MS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $106.10B | $298.41B | -$192.31B | MS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CME REV | MS REV | CME GROSS % | MS GROSS % | CME FCF | MS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $6.52B | $0 | 44.0% | — | $4.19B | -$17.89B |
| FY 2024 | $6.13B | $0 | 44.0% | — | $3.60B | $1.36B |
| FY 2023 | $5.58B | $0 | 44.0% | — | $3.20B | -$33.54B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CME // BETA 1.01
MS // BETA 1.04